Chris VanDeusen, Ph. D.
VP & Chief Scientific Officer
As Chief Scientific Officer, Dr. VanDeusen is responsible for leadership of all of PIC Therapeutics' scientific and development efforts.
Dr. VanDeusen brings over 15 years of experience in the biopharmaceutical sector, with extensive expertise in drug discovery and development. He has contributed to or been the inventor of multiple compounds entering into pre-clinical development.
Previously, he was the head of the Chemistry division within Tissue Protection and Repair at Sanofi and Genzyme, leading global project teams in the areas of inflammation and fibrosis. Dr. VanDeusen is a member of the Scientific Advisory Board for Katexco Pharmaceuticals.
Dr. VanDeusen earned a BA in Chemistry from Wittenberg University and a PhD from Stanford University.